Advertisement

Improved accuracy in DFS pattern interpretation using a novel HEp-2 ELITE system

  • Maria InfantinoEmail author
  • O. Shovman
  • B. Gilburd
  • M. Manfredi
  • V. Grossi
  • Maurizio Benucci
  • A. Damiani
  • D. Chimenti
  • K. Malyavantham
  • Y. Shoenfeld
Original Article
  • 20 Downloads
Part of the following topical collections:
  1. Autoimmune Collection 2018

Abstract

Introduction/objectives

Accurate interpretation of DFS70 (dense fine speckled 70) and mixed antinuclear antibodies (ANAs) patterns can be challenging using conventional HEp-2 immunofluorescence (IIF) method. We evaluated a novel HEp-2 IIF substrate (HEp-2 ELITE/DFS70-KO) composed of a mixture of engineered HEp-2 devoid of the DFS70 autoantigen and conventional HEp-2 cells. The study assessed the utility of the new substrate in ANA screening and its advantages.

Method

One thousand and five consecutive routine samples sent for ANA screening were tested on both standard HEp-2 and the HEp-2 ELITE DFS70 KO substrates (ImmuGlo ANA HEp-2 and HEp-2 ELITE/DFS70-KO, Trinity Biotech, Buffalo, NY). Anti-DFS70 antibody specificity was additionally determined by immunoblot (IB). Clinical and serological data were included in the analysis of the overall impact of the novel HEp-2 substrate on DFS pattern interpretation.

Results

Of the 22 cases suspected as positive for DFS pattern alone or in combination with homogeneous or speckled patterns on conventional HEp-2 cells, 17 were interpreted with a higher accuracy using the new HEp-2 ELITE method as positive for DFS70 (monospecific DFS70 (10), mixed DFS70 (7)), speckled (3), and DFS (2) patterns.

Conclusions

The new substrate was not only useful in deciphering unclear mixed ANA patterns but also highly sensitive in detecting DFS70 pattern in comparison to the DFS70 positivity obtained using IB.

Keywords

Anti-DFS70 Antinuclear antibodies Autoantibodies Autoimmune disease HEp2-cells 

Notes

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    American College of Rheumatology Position Statement (2011) Methodology of testing for antinuclear antibodies. www.rheumatology.org/practice/ana_position_stmt.pdf. Approved by Board of Directors: Aug 2011
  2. 2.
    Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL et al (2015) Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015. Front Immunol 6:412CrossRefGoogle Scholar
  3. 3.
    Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, Bossuyt X, Musset L, Cervera R, Plaza-Lopez A, Dias C, Sousa MJ, Radice A, Eriksson C, Hultgren O, Viander M, Khamashta M, Regenass S, Andrade LEC, Wiik A, Tincani A, Rönnelid J, Bloch DB, Fritzler MJ, Chan EKL, Garcia-de la Torre I, Konstantinov KN, Lahita R, Wilson M, Vainio O, Fabien N, Sinico RA, Meroni P, Shoenfeld Y (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73:17–23CrossRefGoogle Scholar
  4. 4.
    Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69:1420–1422CrossRefGoogle Scholar
  5. 5.
    Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, Tomita Y, Muro Y (2004) Anti-DFS70antibodies in 597 healthy hospital workers. Arthritis Rheum 50:892–900CrossRefGoogle Scholar
  6. 6.
    Malyavantham KS, Suresh L (2018) Simultaneous distinction of Monospecific and mixed DFS70 patterns during ANA screening with a novel HEp-2 ELITE/DFS70 knockout substrate. J Vis Exp 131Google Scholar
  7. 7.
    Malyavantham KL, Suresh L (2017) Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Auto Immun Highlights 8:3CrossRefGoogle Scholar
  8. 8.
    Fritzler MJ (2011) The antinuclear antibody test: last or lasting gasp? Arthritis Rheum 63:19–22CrossRefGoogle Scholar
  9. 9.
    Basu A, Sanchez TW, Casiano CA (2015) DFS70/LEDGF p75: an enigmatic autoantigen at the interface between autoimmunity, AIDS, andcancer. Front Immunol 6:116CrossRefGoogle Scholar
  10. 10.
    Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM (2000) Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 105:1211–1220CrossRefGoogle Scholar
  11. 11.
    Infantino M, Meacci F, Grossi V, Manfredi M, Li Gobbi F, Sarzi-Puttini P, Atzeni F, Benucci M (2017) The clinical impact of anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. Immunol Res 65:293–295CrossRefGoogle Scholar
  12. 12.
    Seelig CA, Bauer O, Seelig HP (2016) Autoantibodies against DFS70/LEDGF exclusion markers for systemic autoimmune rheumatic diseases (SARD). Clin Lab 62:499–517CrossRefGoogle Scholar
  13. 13.
    Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE (2011) Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63:191–200CrossRefGoogle Scholar
  14. 14.
    Mahler M, Parker T, Peebles CL Andrade LE, Swart A, Carbone Y et al (2012) Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 39:2104–2110CrossRefGoogle Scholar
  15. 15.
    Bizzaro N, Tonutti E, Tampoia M, Infantino M, Cucchiaro F, Pesente F, Morozzi G, Fabris M, Villalta D (2015) Specific chemoluminescence and immunoadsorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. Clin Chim Acta 451:271–277CrossRefGoogle Scholar
  16. 16.
    Nilsson AC, Voss A, Lillevang ST (2015) DFS70 autoantibodies are rare in healthy Danish individuals but may still serve as a diagnostic aid. Scand J Immunol 82:547–548CrossRefGoogle Scholar
  17. 17.
    Conrad K, Rober N, Andrade LE, Mahler M (2017) The clinical relevance ofanti-DFS70 autoantibodies. Clin Rev Allergy Immunol 52:202–216CrossRefGoogle Scholar
  18. 18.
    Fritzler MJ (2016) Choosing wisely: review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun Rev 15:272–280CrossRefGoogle Scholar
  19. 19.
    Gundín S, Irure-Ventura J, Asensio E, Ramos D, Mahler M, Martínez-Taboada V, López-Hoyos M (2016) Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective. Auto Immun Highlights 7:10CrossRefGoogle Scholar
  20. 20.
    Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE (2018) Recognition and relevance of anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med (Lausanne) 5:88CrossRefGoogle Scholar
  21. 21.
    Shovman O, Gilburd B, Chayat C, Amital H, Langevitz P, Watad A, Guy A, Perez D, Azoulay D, Blank M, Segal Y, Bentow C, Mahler M, Shoenfeld Y (2018) Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. Clin Exp Rheumatol 36:121–126Google Scholar
  22. 22.
    Infantino M, Shovman O, Pérez D, Manfredi M, Grossi V, Benucci M et al (2018) Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: what’s on the horizon? Rheumatology (Oxford).  https://doi.org/10.1093/rheumatology/key012
  23. 23.
    Ogawa Y, Sugiura K, Watanabe A, Kunimatsu M, Mishima M, Tomita Y, Muro Y (2004) Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. J Autoimmun 23:221–231CrossRefGoogle Scholar
  24. 24.
    Muro Y, Sugiura K, Morita Y, Tomita Y (2008) High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus 17:171–176CrossRefGoogle Scholar
  25. 25.
    Bentow C, Fritzler MJ, Mummert E, Mahler M et al (2016) Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. Auto Immun Highlights 7:8CrossRefGoogle Scholar
  26. 26.
    Bentow C, Rosenblum R, Correia P, Karayev E, Karayev D, Williams D, Kulczycka J, Fritzler MJ, Mahler M (2016) Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. Lupus 25:897–904CrossRefGoogle Scholar
  27. 27.
    Mutlu E, Eyigör M, Mutlu D, Gültekin M (2016) Confirmation of anti-DFS70 antibodies is needed in routine clinical samples with DFS staining pattern. Cent Eur J Immunol 41:6–11CrossRefGoogle Scholar
  28. 28.
    Rigon A, Buzzulini F, Soda P, Onofri L, Arcarese L, Iannello G, Afeltra A (2011) Novel opportunities in automated classification of antinuclear antibodies on HEp-2 cells. Autoimmun Rev 10:647–652CrossRefGoogle Scholar
  29. 29.
    Bizzaro N, Tonutti E, Villalta D (2011) Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: not an easy task! Comment on the article by Mariz et al. Arthritis Rheum 63:4036–4037 author reply 4037–8CrossRefGoogle Scholar
  30. 30.
    Mahler M, Meroni PL, Andrade LE, Khamashta M, Bizzaro N, Casiano CA, Fritzler MJ (2016) Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmun Rev 15:198–201CrossRefGoogle Scholar
  31. 31.
    Bizzaro N, Pesente F, Cucchiaro F, Infantino M, Tampoia M, Villalta D, Fabris M, Tonutti E (2016) Anti-DFS70 antibodies detected by immunoblot methods: a reliable tool to confirm the dense fine speckles ANA pattern. J Immunol Methods 436:50–53CrossRefGoogle Scholar
  32. 32.
    Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman-Goddard G et al (2005) Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci 1050:380–388CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Immunology and Allergology Laboratory UnitS. Giovanni di Dio Hospital, Azienda Usl Toscana CentroFlorenceItaly
  2. 2.Zabludowitz Center for Autoimmune DiseasesSheba Medical CenterRamat GanIsrael
  3. 3.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  4. 4.Rheumatology UnitS. Giovanni di Dio Hospital, Azienda Usl Toscana CentroFlorenceItaly
  5. 5.A.Menarini DiagnosticsFlorenceItaly
  6. 6.Trinity BiotechBuffaloUSA
  7. 7.Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune DiseasesTel Aviv UniversityTel AvivIsrael

Personalised recommendations